Thermo Fisher Scientific Inc. Stock Price Targets

Comprehensive analysis of short, mid, and long-term price targets for Thermo Fisher Scientific Inc. (TMO).

Back to Analysis Hub

Give me a comprehensive price target analysis for Thermo Fisher Scientific Inc. (TMO).

Thermo Fisher Scientific Inc. (TMO) — Comprehensive Analysis Date: 2025-10-10

Below is a data-driven, multi-section analysis of TMO using the data you provided. Per your instruction, I’ve derived Low/Median/High price targets using a forward-earnings-based methodology and drew horizontal lines on the chart for those levels. The lines were extended 30 days ahead from today.

Price target lines drawn on chart

  • Low Target: 469.6
    • Color: #1E90FF (Dodger Blue)
  • Median Target: 540.0
    • Color: #32CD32 (Lime Green)
  • High Target: 610.5
    • Color: #FF4500 (Orange Red)

Assumptions and method for price targets:

  • Forward P/E (next 12 months) provided: 22.762026
  • Current price: 534.68
  • Forward EPS = Price / Forward P/E ≈ 534.68 / 22.762026 ≈ 23.48
  • Price targets derived using 20x, 23x, and 26x forward EPS:
    • Low (20x): 23.48 × 20 ≈ 469.6
    • Median (23x): 23.48 × 23 ≈ 540.0
    • High (26x): 23.48 × 26 ≈ 610.5
  • These targets reflect a disciplined multiple-based method in the absence of a published consensus (see Analyst Targets section). They assume the forward earnings trajectory remains intact and that multiple expansion/compression occurs within a reasonable band.

Executive summary

  • TMO remains a leading player in life sciences tools and diagnostics, with strong gross and operating margins, and substantial cash generation. The forward P/E around 22.8x suggests the stock trades at a higher multiple than the typical broad market average, but aligns with its high-quality growth profile and durable demand in lab instrumentation, bioprocessing, and applied markets.
  • Near-term momentum appears constructive, with the stock trading above the 50-day moving average and a positive MACD. However, the RSI approaching overbought territory (~71) flags some near-term risk of a consolidation or pullback.
  • The lack of published analyst price targets in your dataset means we rely on a forward-earnings framework (and implied multiples) to frame price targets. The derived range (470–611) implies potential upside modestly balanced by potential near-term downside risk if growth drivers decelerate or multiples compress.

Fundamental Analysis Key metrics (current snapshot)

  • Market cap: 201.9B
  • Enterprise value: 231.4B
  • Trailing P/E: 30.96
  • Forward P/E: 22.76
  • Price to Book: 3.997
  • Return on Equity (ROE): 13.42%
  • Return on Assets (ROA): 4.97%
  • Profit margin: 15.24%
  • Gross margin: 41.28%
  • Operating margin: 17.84%
  • Debt to equity: 69.62x
  • Total cash: 6.39B
  • Total debt: 35.23B
  • Dividend yield: 0.32% (five-year avg: 0.24%)
  • Beta: 0.775 (low-to-moderate equity beta; relative strength vs. market)

Balance sheet and leverage insights

  • Net debt (approx): Total debt minus cash ≈ 28.84B
  • Leverage is meaningful but manageable for a high-quality, cash-generative life sciences equipment company, with a long track record of consistent FCF generation and stable margins.
  • Cash generation supports modest dividend growth and potential for strategic buybacks or product/line investments, though current yield remains modest at ~0.32%.

Valuation and financial health takeaway

  • The stock’s trailing P/E (~31x) reflects past growth and higher multiple attribution; the forward P/E (~22.8x) implies reasonable expectations for earnings growth and discounting of near-term cyclicality.
  • Gross and operating margins are sturdy, suggesting pricing power and efficiency in a diversified end-market footprint (laboratories, pharma, academia, diagnostics).

Earnings Analysis Recent earnings summary (selected metrics)

  • 2025-06-30:
    • Net income from continuing operations: 1.617B
    • Diluted EPS: 4.28
    • EBITDA: 2.799B
    • Normalized EBITDA: 2.889B
    • Total revenue: 10.854B
    • Operating income: 1.916B
  • 2025-03-31:
    • Net income from continuing operations: 1.508B
    • Diluted EPS: 3.98
    • EBITDA: 2.628B
    • Normalized EBITDA: 2.726B
    • Total revenue: 10.364B
    • Operating income: 1.816B
  • 2024-12-31:
    • Net income from continuing operations: 1.830B
    • Diluted EPS: 4.78
    • EBITDA: 3.000B
    • Normalized EBITDA: 3.208B
    • Total revenue: 11.395B
    • Operating income: 2.258B
  • 2024-09-30:
    • Net income from continuing operations: 1.630B
    • Diluted EPS: 4.25
    • EBITDA: 2.837B
    • Normalized EBITDA: 2.882B
    • Total revenue: 10.598B
    • Operating income: 2.098B
  • 2024-06-30:
    • Net income from continuing operations: 1.549B
    • Diluted EPS: 4.04
    • EBITDA: 2.917B
    • Normalized EBITDA: 2.988B
    • Total revenue: 10.541B
    • Operating income: 1.897B

EPS Trends

  • Trailing and forward-looking EPS signals (as provided):
    • 0q (current): 5.49908
    • +1q: 6.51492
    • 0y: 22.50561
    • +1y: 24.45602
  • Interpretation:
    • The data imply meaningful year-over-year earnings momentum (0y to +1y), suggesting the market expects mid-to-high single-digit to low-double-digit EPS growth over the next year. The EPS trend aligns with the forward EPS premise used for target derivation.

EPS Revisions

  • 0q (recent horizon):
    • Up last 7 days: 0
    • Up last 30 days: 1
    • Down last 30 days: 3
    • Down last 7 days: 2
  • +1q (next horizon):
    • Up last 7 days: 1
    • Up last 30 days: 2
    • Down last 30 days: 2
    • Down last 7 days: 0
  • 0y (next-year horizon):
    • Up last 7 days: 1
    • Up last 30 days: 3
    • Down last 30 days: 2
    • Down last 7 days: 1
  • +1y (two-year horizon):
    • Up last 7 days: 1
    • Up last 30 days: 2
    • Down last 30 days: 3
    • Down last 7 days: 1
  • Interpretation:
    • Near-term revisions show slightly more downgrades than upgrades (0q, 0y), with a modest uptick in revisions in the +1q window. Overall, revisions are mixed but tilt modestly negative in the near term, with some normalization expected into the longer horizon.

Technical indicators (last 60 days)

  • 50-day moving average (MA): last listed value around 486.5 on 2025-10-09
  • RSI (14): around 71.1 (near overbought territory)
  • MACD (12,26,9): MACD around 16.2; Signal around 10.1 (bullish momentum)
  • Current price: 534.7 (as of 2025-10-09 close shown in data)
  • Interpretation:
    • Price trades well above the 50-day MA, consistent with a bullish intermediate trend.
    • RSI indicates elevated momentum and potential near-term pullback risk if momentum fades.
    • MACD is positive with a widening gap, supporting trend strength but watch for any MACD crossovers that may signal consolidation.

Analyst Consensus & Price Targets

  • Analyst price targets: Not provided in the dataset (empty). No explicit low/median/high consensus numbers are available here.
  • Number of analysts: Not provided.
  • Catalysts to watch:
    • New product launches, pipeline expansions in bioprocessing and diagnostics.
    • Margin expansion or contraction driven by product mix and amortization of R&D.
    • Macro health of life sciences funding and academic/biotech capex cycles.

Price Target Analysis (Short, Mid, Long-Term) Derived targets (based on forward EPS and multiples)

  • Forward EPS (approx): ~23.48
  • Low Target (20x forward EPS): ~469.6
  • Median Target (23x forward EPS): ~540.0
  • High Target (26x forward EPS): ~610.5
  • Current price: 534.7
  • Interpretation:
    • Short-term (3 months): The stock could hover near current levels with risk of a modest pullback given overbought RSI, potentially testing the low-470s if market breadth worsens. If momentum remains, resistance at the 540 area could be tested.
    • Mid-term (12 months): If the company sustains earnings momentum and multiples stay around the current forward P/E, the median target near 540 could be a reasonable baseline with potential upside toward 610 if multiples firm or if earnings beat expectations.
    • Long-term (3+ years): Structural growth in life sciences instrumentation, ongoing innovation, and solid free cash flow generation could sustain higher multiples and push price toward the upper end of the implied range (around 610+), contingent on macro health and competitive dynamics.

Note: Without published consensus targets in the dataset, the above price targets are derived from a disciplined forward-earnings framework (forward EPS and multiple ranges). They are not a substitute for actual broker targets, but provide a framework for valuation discourse.

Technical Analysis — Current price action and key levels

  • Price action: Trading above the 50-day MA indicates a bullish intermediate trend. The MACD is positive and rising, signaling ongoing upside momentum.
  • Key support/resistance:
    • Near-term support: around the 50-day MA (~$486) and historical consolidation levels below.
    • Near-term resistance: the 540 area (our median target) and then the 610 area (our high target).
  • RSI and momentum: RSI around 71 suggests overbought conditions; careful monitoring for any reversion or consolidation.
  • Moving average trend: 50-day MA trending upwards; longer-term trend not provided but price performance supports a positive stance.

Key Risks & Opportunities

  • Key Risks
    • Potential multiple compression if growth guidance slows or if market breadth deteriorates for high-quality healthcare equipment names.
    • Macro headwinds (biotech capex cycles, currency effects, regulated capex delays) could dampen near-term demand.
    • Elevated gross margins could face pressure if input costs rise or if product mix shifts toward lower-margin lines.
  • Key Opportunities
    • Ongoing demand for lab instrumentation and bioprocess solutions in pharma/biotech could sustain attractive growth.
    • Share repurchases or disciplined capital allocation could support earnings per share even in a stable revenue environment.
    • Product pipeline momentum and cost-efficient manufacturing improvements can sustain margin resilience.

Investment Recommendation

  • With a solid fundamental base, margin stability, and a constructive technical backdrop, the posture is modestly bullish for the next 12–24 months, with a bias toward a stock that could trade within a broad range depending on market risk appetite and earnings cadence.
  • Recommendation: Hold to Moderate Buy (with upside potential toward the 540–610 target band if earnings meet/beat estimates and multiples remain supported).
  • Expected return potential (12–24 months): Roughly 5–15% to the median target, with potential upside into the ~14–15% range to the high target under favorable macro and company-specific catalysts.

Appendix: Price targets, lines drawn, and key data sources

  • Price target lines drawn (30-day extension):
    • Low Target: 469.6 (Blue)
    • Median Target: 540.0 (Green)
    • High Target: 610.5 (Orange)
  • Data sources and references used in this analysis:
    • Market data, valuations, and key metrics (current price, market cap, EV, P/Es, margins, debt, cash, dividend yield, beta) as provided.
    • Recent earnings summary (quarterly results with Net Income, EPS, EBITDA, Revenue, and margins).
    • EPS Trend data (current, +1q, 0y, +1y) and EPS revisions (up/down counts across 7d/30d/60d horizons).
    • Technical indicators (50-day MA, RSI, MACD) for the last 60 days.
    • Forward P/E and implied forward EPS used to derive the price targets above.

Markdown tables: Key data snapshots

  1. Valuation & Financial Health (selected metrics)

  • Table: Key Metrics

  • Source: Provided dataset

  • Metric | Value

  • Current price | 534.68

  • Market cap | 201,901,654,016

  • Enterprise value | 231,401,848,832

  • Trailing P/E | 30.96

  • Forward P/E | 22.76

  • P/B | 3.997

  • ROE | 13.42%

  • ROA | 4.97%

  • Profit margin | 15.24%

  • Gross margin | 41.28%

  • Operating margin | 17.84%

  • Debt/Equity | 69.62

  • Total cash | 6,390,000,128

  • Total debt | 35,228,999,680

  • Net debt (approx) | 28,838,869,552

  • Dividend yield | 0.32%

  • Five-year avg dividend yield | 0.24%

  • Beta | 0.775

  1. Recent Earnings Summary (selected metrics)
  • Table: Quarterly Earnings Snapshot
  • Period | Net Income (USD) | Diluted EPS | EBITDA | Normalized EBITDA | Revenue
  • 2025-06-30 | 1,617,000,000 | 4.28 | 2,799,000,000 | 2,889,000,000 | 10,854,000,000
  • 2025-03-31 | 1,507,000,000 | 3.98 | 2,628,000,000 | 2,726,000,000 | 10,364,000,000
  • 2024-12-31 | 1,830,000,000 | 4.78 | 3,000,000,000 | 3,208,000,000 | 11,395,000,000
  • 2024-09-30 | 1,630,000,000 | 4.25 | 2,837,000,000 | 2,882,000,000 | 10,598,000,000
  • 2024-06-30 | 1,548,000,000 | 4.04 | 2,917,000,000 | 2,988,000,000 | 10,541,000,000
  1. EPS Trend and Revisions

  • Table: EPS Trend

  • Period | Current EPS | 7 days ago | 30 days ago | 60 days ago | 90 days ago

  • 0q | 5.49908 | 5.50034 | 5.50091 | 5.50476 | 5.52764

  • +1q | 6.51492 | 6.50938 | 6.50389 | 6.51356 | 6.39917

  • 0y | 22.50561 | 22.50620 | 22.50349 | 22.49362 | 22.363

  • +1y | 24.45602 | 24.46016 | 24.44266 | 24.46570 | 24.69348

  • Table: EPS Revisions (counts)

  • Horizon | Up Last 7d | Up Last 30d | Down Last 30d | Down Last 7d

  • 0q | 0 | 1 | 3 | 2

  • +1q | 1 | 2 | 2 | 0

  • 0y | 1 | 3 | 2 | 1

  • +1y | 1 | 2 | 3 | 1

  1. Technical Indicators (last 60 days)
  • 50-day MA (latest): 486.5
  • RSI (14): 71.1
  • MACD (12,26,9): MACD 16.2, Signal 10.1
  • Last price (example): 534.7
  1. Price Target Summary (derived targets)
  • Target type | Price (USD) | Basis
  • Low Target | 469.6 | 20x forward EPS (~23.48)
  • Median Target | 540.0 | 23x forward EPS (~23.48)
  • High Target | 610.5 | 26x forward EPS (~23.48)

Charting note

  • Horizontal lines drawn from 2025-10-10 through 2025-11-09 with the specified colors and target prices:
    • Low: 469.6 (Blue)
    • Median: 540.0 (Green)
    • High: 610.5 (Orange)

Bottom line

  • TMO offers a compelling quality story with durable margins and strong growth momentum in life sciences. The forward multiple is reasonable given earnings expectations, but near-term momentum signals elevated risk of short-term consolidation due to overbought conditions (RSI ~71). The implied price target range (approximately 470–611) provides a structured view of potential upside and downside, contingent on earnings delivery and multiple stability. With a Hold-to-Buy stance, investors may look for a pullback toward the 500s as a more favorable entry point, while remaining mindful of the macro and sector dynamics.

If you’d like, I can tighten the price target framework to incorporate alternative multiples (e.g., 19x/21x for a more conservative view) or add sensitivity analysis around changes in forward EPS assumptions.

Chart is loading...